Why Do Some Concentrated Insulins Maintain Their Pharmacokinetics/Pharmacodynamics Profile?

@article{Hood2017WhyDS,
  title={Why Do Some Concentrated Insulins Maintain Their Pharmacokinetics/Pharmacodynamics Profile?},
  author={Robert C. Hood},
  journal={Diabetes technology & therapeutics},
  year={2017},
  volume={19 4},
  pages={
          203-205
        }
}
Insulin time action can be characterized by evaluating parameters of either insulin levels (pharmacokinetics or PK) or insulin action using glucose infusion rate (GIR) during insulin clamp studies (pharmacodynamics or PD). Why is it that two commercially available concentrated insulin preparations have a right-shifted PK/PD (e.g., longer Tmax, lower Cmax, and longer duration of action) compared to their U-100 counterparts and two do not? There are factors that affect the PK/PD of exogenous… CONTINUE READING
1 Citations
35 References
Similar Papers

Citations

Publications citing this paper.

References

Publications referenced by this paper.
Showing 1-10 of 35 references

Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects. Diabetes Care 2011;34:2496–2501

  • A de la Peña, M Riddle, LA Morrow
  • 2011
Highly Influential
4 Excerpts

Faster onset and greater early exposure and glucoselowering effect with fasteracting insulin aspart vs . insulin aspart : a pooled analysis in subjects with type 1 diabetes

  • T Heise, TR Pieber, T Danne
  • Diabetes
  • 2016

Ultrastructural 3 D visualization of insulin degludec multihexamers upon subcutaneous injection in pig

  • T Seested, A Burgess, C Pyke
  • Diabetes
  • 2016

Ultrastructural 3D visualization of insulin degludec multihexamers upon subcutaneous injection in pig. Diabetes 2016;65 suppl 1:918P

  • T Seested, A Burgess, C Pyke
  • 2016
1 Excerpt

Similar Papers

Loading similar papers…